Prescription Drugs

;

Comments on drug pricing transparency interim final rule [CMS-9905-IFC]

Jan 21, 2022

We are pleased that the Biden administration is moving forward with the requirement that insurance plans must report on various data points associated with prescription drug spending. We believe with this greater understanding and transparency of prescription drug costs, you can better implement policies and measures that increase competition, improve prescription drug affordability and access for the American people.

read more

Comments on prescription drug limitations in proposed Oregon Medicaid waiver

Jan 7, 2022

The HIV+Hepatitis Policy Institute write[s] to express our strong opposition to the proposed limits to the prescription drug formulary that have been included as part of Oregon’s 1115 Medicaid Demonstration Waiver. The stated goal of the waiver is to promote greater equity; however, not only do we believe what Oregon is proposing is not legal, but it will have the opposite effect of promoting equity. We urge you to not include these proposals in your waiver submission.

read more

Letter to Senate Finance Committee on concerns with drug pricing proposals

Oct 6, 2021

We, the undersigned 46 organizations, on behalf of millions of American patients who live with complex, chronic health conditions such as HIV, autoimmune diseases, cancer, diabetes, lupus, multiple sclerosis, and hepatitis, are pleased that your committee and Congress are focused on advancing policies and measures that improve prescription drug affordability and access for the American people. We believe there are clear actions that Congress can take right now to help patients access, afford, and adhere to the medications they need to stay healthy. However, several proposals on the table would create great challenges for those we serve and have negative implications for vulnerable communities and future treatment innovations.

read more

Letter in support of improving patient drug affordability through standardized benefit plans

Jul 28, 2021

We, the undersigned 40 organizations, on behalf of millions of patients and American consumers who live with complex conditions such as HIV, autoimmune diseases, cancer, diabetes, lupus, hemophilia, and hepatitis, write in response to the request for comments on the proposed rule that would amend the 2022 payment and parameters rule. The patients we represent appreciate all you are doing to make healthcare more accessible and affordable for beneficiaries. There are many aspects of the proposed rule that we support; however, one issue that we would like to focus on is your desire to offer standardized options for qualified health plans beginning in 2023.

read more

Search

Categories

Tags

ACA Appropriations Biden administration CDC co-pay accumulators Congress copay copay accumulator Copay accumulators Copay assistance Cost-sharing COVID-19 Drug Pricing FDA Gay men healthcare Hepatitis Hepatitis B hepatitis C Hepatitis Prevention HHS HIV HIV Prevention Insurers Medicaid medicare Medicare Part D NAIC NIH PBM PBMs PrEP Prescription Drugs Private Insurance Ryan White Program state STDs Syringe services Testing transparency Treatment Trump administration women

Recent Testimony, Letters, Comments

Pin It on Pinterest